# Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling

Rafael Perera, 1\* Emily McFadden, 1 Julie McLellan, 1
Tom Lung, 2 Philip Clarke, 2 Teresa Pérez, 1
Thomas Fanshawe, 1 Andrew Dalton, 1
Andrew Farmer, 1 Paul Glasziou, 3 Osamu Takahashi, 4
John Stevens, 5 Les Irwig, 6 Jennifer Hirst, 1
Sarah Stevens, 1 Asuka Leslie, 4 Sachiko Ohde, 4
Gautam Deshpande, 4 Kevin Urayama, 4 Brian Shine 7
and Richard Stevens 1

**Declared competing interests of authors:** none

<sup>&</sup>lt;sup>1</sup>National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

<sup>&</sup>lt;sup>2</sup>Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia

<sup>&</sup>lt;sup>3</sup>Bond University, Gold Coast, Australia

<sup>&</sup>lt;sup>4</sup>St Luke's International University Center for Clinical Epidemiology, Tokyo, Japan

<sup>&</sup>lt;sup>5</sup>Patient and public involvement representative, UK

<sup>&</sup>lt;sup>6</sup>Sydney School of Public Health, University of Sydney, Sydney, Australia

<sup>&</sup>lt;sup>7</sup>Oxford University Hospitals Trust, Oxford, UK

<sup>\*</sup>Corresponding author

# **Plain English summary**

## Monitoring lipid levels in patients with CVD

Health Technology Assessment 2015; Vol. 19: No. 100

DOI: 10.3310/hta191000

NIHR Journals Library www.journalslibrary.nihr.ac.uk

## **Plain English summary**

There is a clear relationship between cholesterol levels and the risk of heart disease (including heart attack and stroke). It is common that, together with other factors such as blood pressure, cholesterol levels are measured at regular intervals to determine a person's risk of heart disease and hence decide whether or not cholesterol-lowering drugs (statins) should be prescribed. There are several alternative cholesterol measures ('lipids'). Over short time periods, cholesterol measures may vary more by chance than by any real change in health status. Therefore, we studied which cholesterol measures are most strongly associated with future heart disease, and the appropriate length of time to leave between one cholesterol test and the next.

First, we compiled information from previous studies and found that, in general, combinations of cholesterol measures (e.g. the ratio of two types of cholesterol) show stronger associations with heart disease than single measures. We used similar methods to study the effects of statins on cholesterol. This confirmed that effects are greater at higher doses. Finally, we used computer models based on routine general practice data to estimate the levels of treatment, financial costs and rates of outcomes such as heart disease, if cholesterol is measured every 1, 2, 3 or 5 years. Based on our models, the shorter the interval, the larger the number of people that will be eligible for treatment.

Within limitations, including the difficulty of fully quantifying harms and benefits of statins in a computer model, we estimate that this is both beneficial and cost-saving.

#### HTA/HTA TAR

## **Health Technology Assessment**

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 5.116

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

#### Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

#### HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

#### This report

The research reported in this issue of the journal was funded by the HTA programme as project number 10/97/01. The contractual start date was in January 2012. The draft report began editorial review in April 2014 and was accepted for publication in December 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2015. This work was produced by Perera et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

# **Editor-in-Chief of Health Technology Assessment and NIHR Journals Library**

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

#### **NIHR Journals Library Editors**

**Professor Ken Stein** Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Professor Aileen Clarke** Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson Director of NETSCC, HTA, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

**Professor Elaine McColl** Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie Health Services Research Unit, University of Aberdeen, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk